TY - JOUR
T1 - Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia
T2 - A systematic review and meta-analysis
AU - ECNP Physical And meNtal Health Thematic Working Group (PAN-Health)
AU - Solmi, Marco
AU - Croatto, Giovanni
AU - Fornaro, Michele
AU - Schneider, Lynne Kolton
AU - Rohani-Montez, S Christy
AU - Fairley, Leanne
AU - Smith, Nathalie
AU - Bitter, István
AU - Gorwood, Philip
AU - Taipale, Heidi
AU - Tiihonen, Jari
AU - Cortese, Samuele
AU - Dragioti, Elena
AU - Rietz, Ebba Du
AU - Nielsen, Rene Ernst
AU - Firth, Joseph
AU - Fusar-Poli, Paolo
AU - Hartman, Catharina
AU - Holt, Richard I G
AU - Høye, Anne
AU - Koyanagi, Ai
AU - Larsson, Henrik
AU - Lehto, Kelli
AU - Lindgren, Peter
AU - Manchia, Mirko
AU - Nordentoft, Merete
AU - Skonieczna-Żydecka, Karolina
AU - Stubbs, Brendon
AU - Vancampfort, Davy
AU - Boyer, Laurent
AU - De Prisco, Michele
AU - Vieta, Eduard
AU - Correll, Christoph U
N1 - Copyright © 2023. Published by Elsevier B.V.
PY - 2024/3
Y1 - 2024/3
N2 - People with schizophrenia die prematurely, yet regional differences are unclear. PRISMA 2020-compliant systematic review/random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) versus any control group, and moderators, in people with ICD/DSM-defined schizophrenia, comparing countries and continents. We conducted subgroup, meta-regression analyses, and quality assessment. The primary outcome was all-cause mortality. Secondary outcomes were suicide-, /natural-cause- and other-cause-related mortality. We included 135 studies from Europe (n = 70), North-America (n = 29), Asia (n = 33), Oceania (n = 2), Africa (n = 1). In incident plus prevalent schizophrenia, differences across continents emerged for all-cause mortality (highest in Africa, RR=5.98, 95 %C.I.=4.09-8.74, k = 1, lowest in North-America, RR=2.14, 95 %C.I.=1.92-2.38, k = 16), suicide (highest in Oceania, RR=13.5, 95 %C.I.=10.08-18.07, k = 1, lowest in North-America, RR=4.4, 95 %C.I.=4.07-4.76, k = 6), but not for natural-cause mortality. Europe had the largest association between antipsychotics and lower all-cause mortality/suicide (Asia had the smallest or no significant association, respectively), without differences for natural-cause mortality. Higher country socio-demographic index significantly moderated larger suicide-related and smaller natural-cause-related mortality risk in incident schizophrenia, with reversed associations in prevalent schizophrenia. Antipsychotics had a larger/smaller protective association in incident/prevalent schizophrenia regarding all-cause mortality, and smaller protective association for suicide-related mortality in prevalent schizophrenia. Additional regional differences emerged in incident schizophrenia, across countries, and secondary outcomes. Significant regional differences emerged for all-cause, cause-specific and suicide-related mortality. Natural-cause death was homogeneously increased globally. Moderators differed across countries. Global initiatives are needed to improve physical health in people with schizophrenia, local studies to identify actionable moderators.
AB - People with schizophrenia die prematurely, yet regional differences are unclear. PRISMA 2020-compliant systematic review/random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) versus any control group, and moderators, in people with ICD/DSM-defined schizophrenia, comparing countries and continents. We conducted subgroup, meta-regression analyses, and quality assessment. The primary outcome was all-cause mortality. Secondary outcomes were suicide-, /natural-cause- and other-cause-related mortality. We included 135 studies from Europe (n = 70), North-America (n = 29), Asia (n = 33), Oceania (n = 2), Africa (n = 1). In incident plus prevalent schizophrenia, differences across continents emerged for all-cause mortality (highest in Africa, RR=5.98, 95 %C.I.=4.09-8.74, k = 1, lowest in North-America, RR=2.14, 95 %C.I.=1.92-2.38, k = 16), suicide (highest in Oceania, RR=13.5, 95 %C.I.=10.08-18.07, k = 1, lowest in North-America, RR=4.4, 95 %C.I.=4.07-4.76, k = 6), but not for natural-cause mortality. Europe had the largest association between antipsychotics and lower all-cause mortality/suicide (Asia had the smallest or no significant association, respectively), without differences for natural-cause mortality. Higher country socio-demographic index significantly moderated larger suicide-related and smaller natural-cause-related mortality risk in incident schizophrenia, with reversed associations in prevalent schizophrenia. Antipsychotics had a larger/smaller protective association in incident/prevalent schizophrenia regarding all-cause mortality, and smaller protective association for suicide-related mortality in prevalent schizophrenia. Additional regional differences emerged in incident schizophrenia, across countries, and secondary outcomes. Significant regional differences emerged for all-cause, cause-specific and suicide-related mortality. Natural-cause death was homogeneously increased globally. Moderators differed across countries. Global initiatives are needed to improve physical health in people with schizophrenia, local studies to identify actionable moderators.
U2 - 10.1016/j.euroneuro.2023.12.010
DO - 10.1016/j.euroneuro.2023.12.010
M3 - Review article
C2 - 38368796
SN - 0924-977X
VL - 80
SP - 55
EP - 69
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
ER -